1. Stats
  2. USPTO
  3. TC 1600
  4. Group 1620
  5. Art Unit 1625
  6. Examiner Kosar (SPE)

Examiner Kosar Andrew D (SPE)

1625-KOSAR-ANDREW-D

Employment Information

Art Unit:1625 — Drug, bio-affecting and body treating compositions
Group:1620 — Biomedicinal Chemistry
Classes: 514 — Drug, bio-affecting and body treating compositions
546 — Organic compounds -- part of the class 532-570 series
549 — Organic compounds -- part of the class 532-570 series
544 — Organic compounds -- part of the class 532-570 series
Phone:(571) 272-0913
Email:None
Location:None
Title:Supvy Pat Examnr Gen Chem
Service:22 years
Grade:GS-15

Grant Rate and Difficulty Ranking

98
3-Year Grant rate: 0% over 11 cases
Difficulty: Extremely Hard
Difficulty Percentile: 98th

With Examiner Kosar (SPE), you have a 0% chance of getting an issued patent by 3 years after the first office action. Examiner Kosar (SPE) is an extremely hard examiner and in the 98th percentile across all examiners (with 100th percentile most difficult).

Grant Rate

Grant Rate Timeline

Below is the grant rate timeline for Examiner Kosar (SPE), where the timeline is relative to the date of the first office action. The three-year grant rate is the percentage of applications granted at three years after the first office action.

Comparison with Art Unit 1625

Examiner Kosar (SPE)'s grant rate is lower than that of Art Unit 1625 and lower than that of the USPTO.

Average Office Actions Per Grant
Examiner Kosar (SPE) 0.6
Art Unit 1625 1.1

Interview Benefit

Grant Rate without Interview

Examiner Kosar (SPE) has granted 0 of 11 cases without any applicant-requested interviews for a grant rate of 0%.

Grant Rate with Interview

Examiner Kosar (SPE) has granted 0 of 0 cases with at least one applicant-requested interview for a grant rate of 0%.

Interview Benefit

With Examiner Kosar (SPE), conducting an interview increases your chance of getting a patent granted by 100%.

Recent Dispositions

Recent Dispositions

Number Title OA Rejections Status IFW
18632528 Intermittent Dosing Of Mdm2 Inhibitor Rejection information available with a Premium Stats subscription. See our pricing. Abandoned View
18611335 Inhibiting Mutant Isocitrate Dehydrogenase 1 (Midh-1) Abandoned View
18172927 Method Of Treating Amyotrophic Lateral Sclerosis With Pridopidine Abandoned View
18041540 Pyrimidine Ring Compound Patented View
17997675 Preparation Of Compounds Having Pesticidal Activity Abandoned View
18010731 Treatment For Human Coronavirus Infection Abandoned View
17925493 Inhibitors Of Mlh1 And/or Pms2 For Cancer Treatment Patented View
17740624 Compositions And Methods For Treating Cancer Abandoned View
17905076 Compositions And Methods Containing Reduced Nicotinamide Riboside For Prevention And Treatment Of Pancreatic Diseases And Conditions Abandoned View
18007940 Ror Gamma T Inhibitors And Topical Uses Thereof Abandoned View
17918791 Pirfenidone For Coronavirus Treatment Abandoned View
17915376 Staining Method, Microscopic Observation Method, Staining Agent And Staining Kit Abandoned View
17755366 Cd4 Mimic Compound With Anti-Hiv Activity Patented View
18212444 Carboxamide Compounds And Uses Thereof Patented View
18040552 Crystalline Forms Of 4-(7-Hydroxy-2-Isopropyl-4-Oxo-4h-Quinazolin-3-Yl)-Benzonitrile And Formulations Thereof Patented View
18106273 2-Aminoindane Compounds For Mental Disorders Or Enhancement Patented View
17934772 Compounds, Compositions And Methods Patented View
17699061 Process For The Production Of Alpha-Tocotrienol And Derivatives Abandoned View
17734413 Exo-Aza Spiro Inhibitors Of Menin-Mll Interaction Abandoned View
17695162 Protection Of Plant Extracts And Compounds From Degradation Abandoned View
17632004 A-Substituted Phenyl Structure-Containing Compound, Preparation Method Thereof, And Disinfectant Abandoned View
17954152 Cytotoxic Agents Abandoned View
17875770 Oxoacridinyl Acetic Acid Derivatives And Methods Of Use Abandoned View
17221178 Gaboxadol For Reducing Risk Of Suicide And Rapid Relief Of Depression Abandoned View
17602206 Phosphatidylinositol 3-Kinase Inhibitors Abandoned View
15422264 Hdac1/2 Inhibitors For The Treatment Of Neurodegenerative And/or Cognitive Disorders Abandoned View
15073352 Benzamide Derivatives And Their Use As Hsp90 Inhibitors Abandoned View
15299203 Polymorphic Forms Of 3-(4-Amino-1-Oxo-1,3 Dihydro-Isoindol-2-Yl)-Piperidine-2,6-Dione Abandoned View
15299243 Polymorphic Forms Of 3-(4-Amino-1-Oxo-1,3 Dihydro-Isoindol-2-Yl)-Piperidine-2,6-Dione Abandoned View
15411510 Benzisoxazoles Abandoned View
15311322 Enantiopure Haptens For Nicotine Vaccine Development Abandoned View
15299164 Polymorphic Forms Of 3-(4-Amino-1-Oxo-1,3 Dihydro-Isoindol-2-Yl)-Piperidine-2,6-Dione Abandoned View
15400820 C5ar Antagonists Abandoned View
15091776 Pyridinoylpiperidines As 5-Ht1f Agonists Abandoned View

Appeals Statistics

Purchase Subscription

Subscribe to Premium Examiner Statistics for unlimited access for your law firm.

Disclaimer: We do not provide any guarantees as to the accuracy of the statistics presented above and under
no circumstances will we be liable for any outcome resulting from your reliance on the above statistics.